Skip to main content
Fig. 11 | Journal of Hematology & Oncology

Fig. 11

From: The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

Fig. 11

Schematic diagram showing the effect of YM101 on Cancer-Immunity Cycle and tumor cells. Firstly, YM101 promoted T cell infiltration by restraining the activity of carcinoma-associated fibroblast (CAF). Secondly, YM101 enhanced the tumor-killing activity of T cells by blocking PD-1/PD-L1 and naturalizing TGF-β. Thirdly, YM101 altered the polarization of macrophages and increased the ratio of M1/M2. Besides, YM101 increased the density of dendritic cells (DCs) which would be favorable to antigen presentation in the TME. Lastly, YM101 counteracted epithelial-mesenchymal transition (EMT) in tumor cells

Back to article page